Last update June 25, 2022

Pimozide

Likely Compatibility

Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.

It is a typical, first generation antipsychotic with general properties similar to those of chlorpromazine, that is used for the treatment of schizophrenia and other psychoses and Gilles de la Tourette’s syndrome. Oral administration.

Since the last update we have not found published data on its excretion in breastmilk.

Its high percentage of protein binding and moderately high molecular weight make it unlikely that significant quantities will pass into breast milk.

Product with very few bibliographical references and marketed in few countries.

It may cause increased prolactin levels. (Roke 2009)

Until there is more published data on this drug in relation to breastfeeding, safer known alternatives may be preferable (Parikh 2014, Klinger 2013), especially during the neonatal period and in cases of prematurity.


See below the information of this related product:

Alternatives

We do not have alternatives for Pimozide.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Pimozide in other languages or writings:

  • بيموزيد (Arabic)
  • Пимозид (Cyrillic)
  • 匹莫齐特 (Chinese)
  • ピモジド (Japanese)
  • 1-{1-[4,4-Bis(4-fluorophenyl)butyl]-4-piperidyl}benzimidazolin-2-one; 1-{1-[3-(4,4′-Difluorobenzhydryl)propyl]-4-piperidyl}benzimidazolin-2-one (Chemical name)
  • C28H29F2N3O (Molecular formula)
  • N05AG02 (ATC Code/s)

Groups

Pimozide belongs to these groups or families:

Tradenames

Main tradenames from several countries containing Pimozide in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 50 %
Molecular weight 462 daltons
Protein Binding 99 %
pKa 12.9 -
Tmax 8 (4 - 12) hours
T½ 29 ± 10 hours

References

  1. Parikh T, Goyal D, Scarff JR, Lippmann S. Antipsychotic drugs and safety concerns for breast-feeding infants. South Med J. 2014 Abstract
  2. AA Pharma. Pimozide. Drug Summary. 2014 Full text (in our servers)
  3. Klinger G, Stahl B, Fusar-Poli P, Merlob P. Antipsychotic drugs and breastfeeding. Pediatr Endocrinol Rev. 2013 Mar-Apr;10(3):308-17. Review. Abstract
  4. Roke Y, van Harten PN, Boot AM, Buitelaar JK. Antipsychotic medication in children and adolescents: a descriptive review of the effects on prolactin level and associated side effects. J Child Adolesc Psychopharmacol. 2009 Aug;19(4):403-14. Abstract

Total visits

3,469

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM